TerminatedPhase 2NCT05785819
A Phase 2 Study of VLX-1005 Versus Placebo in Suspected Heparin Induced Thrombocytopenia
Studying Autoimmune heparin-induced thrombocytopenia
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- Veralox Therapeutics
- Principal Investigator
- John Alexander, MDDuke Clinical Research Institute
- Intervention
- VLX-1005(drug)
- Enrollment
- 24 enrolled
- Eligibility
- 18 years · All sexes
- Timeline
- 2023 – 2025
Study locations (14)
- Stanford University, Stanford, California, United States
- University of Colorado, Aurora, Colorado, United States
- Yale University, New Haven, Connecticut, United States
- Georgetown University, Washington D.C., District of Columbia, United States
- MedStar Washington Hospital Center, Washington D.C., District of Columbia, United States
- University of Michigan, Ann Arbor, Michigan, United States
- Mayo Clinic, Rochester, Minnesota, United States
- Duke University, Durham, North Carolina, United States
- Oregon Health and Science University, Portland, Oregon, United States
- Universiy of Pennsylvania, Philadelphia, Pennsylvania, United States
- Thomas Jefferson University, Philadelphia, Pennsylvania, United States
- Carilion Medical Center, Roanoke, Virginia, United States
- University of Washington, Seattle, Washington, United States
- Versiti at Froedtert Hospital, Milwaukee, Wisconsin, United States
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT05785819 on ClinicalTrials.gov